Clareon Panoptix Pro IOL (Alcon) approved in Canada

News
Article

The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation

A Canadian flag in front of a mountain range. Concept image for Alcon Clareon Panoptix Pro intraocular lens IOL launch and approval in Canada. Image credit: ©toptop54 from pixabay - Canva.com

The PanOptix Pro lens is currently available in the single-use Clareon AutonoMe preloaded delivery system, with the Clareon Monarch IV delivery system to be made available in early 2026. Image credit: ©toptop54 from pixabay - Canva.com

Alcon’s Clareon Panoptix Pro IOL has been approved for patients with cataracts in Canada.1 The IOL utilises the company’s proprietary ENLIGHTEN NXT Optical technology, which delivers the lowest light scatter and highest reported light utilisation of any trifocal IOL, according to a news release.

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,” said Rob Scott, vice president of Intraocular Devices, R&D at Alcon, in the release. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”

PanOptix Pro has demonstrated a 94% light utilisation compared to a theoretical maximum utilisation of 96% for diffractive optics. This allows for a more uninterrupted light distribution from distance to near, with a 16% increase in optical image contrast between distance and intermediate. The IOL features a clinically-proven low visual disturbance profile, which promotes high spectacle independence and high patient satisfaction.1

PanOptix Pro is offered at a +2.17 diopter intermediate and a +3.25 diopter near add power. All of Alcon’s IOLs are also available with blue light and UV filtering.1

“PanOptix has been a cornerstone of my cataract practice for 8 years,” said Rosa Braga-Mele, MD, MEd, FRCSC, professor of ophthalmology at the University of Toronto, in the release. “These lenses have consistently delivered outstanding visual outcomes for my patients – a low visual disturbance profile and a happy patient with greater spectacle independence. So, it’s exciting to see this technology evolve to further meet patients’ visual expectations."

The PanOptix Pro lens is available in Canada through Alcon in the single-use Clareon AutonoMe preloaded delivery system, with the Clareon Monarch IV delivery system to be made available in early 2026.1

The lens is also available as the Clareon PanOptix IOL and Clareon Vivity IOL. The PanOptix lens was the first trifocal lens in the US. Clinical trials of the Vivity lens showed a binocular mean uncorrected distance visual acuity of 20/20, a binocular mean uncorrected intermediate visual acuity (26 in) >20/25, and a binocular mean uncorrected near visual acuity (16 in) of 20/32.2

Alcon’s Clareon IOL collection consists of presbyopia-mitigating trifocal lenses and monofocal lenses, both with toric options. Clareon Toric IOLs manage astigmatism with axial and rotational stability. Fibronectin in the lens has been demonstrated to help bind the material to the capsule, anchoring the lens in place to help reduce posterior capsular opacification and improve stability, according to Alcon.2

References

  1. Alcon introduces Clareon PanOptix Pro in Canada, delivering the lowest light scatter of any trifocal IOL. News release. Alcon. June 20, 2025. Accessed June 23, 2025. https://www.businesswire.com/news/home/20250620166312/en/Alcon-Introduces-Clareon-PanOptix-Pro-in-Canada-Delivering-the-Lowest-Light-Scatter-of-any-Trifocal-IOL
  2. (Light) to the power of pro. MyAlconProfessionals. Accessed June 23, 2025. https://www.myalcon.com/professional/cataract-surgery/iols/clareon-iol/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.